MBRX icon

Moleculin Biotech
MBRX

Overview Fund Activity

23 hedge funds and large institutions have $5.26M invested in Moleculin Biotech in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
23
Holders Change
-3
Holders Change %
-11.54%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$107K
2
SPC
2
Sigma Planning Corp
Michigan
$102K
3
State Street
3
State Street
Massachusetts
$127K
4
Envestnet Asset Management
4
Envestnet Asset Management
Illinois
$19K
5
Two Sigma Advisers
5
Two Sigma Advisers
New York
$43K

Top Sellers

1
VF
1
Virtu Financial
New York
$0
2
TSS
2
Two Sigma Securities
New York
$0
3
OQS
3
Occudo Quantitative Strategies
Florida
$0
4
SFI
4
Susquehanna Fundamental Investments
Pennsylvania
$0
5
Goldman Sachs
5
Goldman Sachs
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Goldman Sachs
26
Goldman Sachs
New York
– -$22K -788 Closed
MIFH
27
Migdal Insurance & Financial Holdings
Israel
– -$2K -95 Closed
1
2